Swiss Nordic Bio 2020
Watch the video
NextCell Pharma Expert Event was held on October 8.
Recently, NextCell Pharma announced positive results in its phase II trial, ProTrans-2, showing a statistically significant improved preservation of insulin production in T1D patients.
Cell therapy specialist Prof. Daniel J. Weiss gives an introduction to mesenchymal stem cells and the significance of the study results. Diabetes specialist Prof. Mona Landin-Olsson elaborates on ProTrans’ clinical relevance and the value of preserving patients’ endogenous insulin production.
NextCell Pharma’s CEO Mathias Svahn presents the study results and the roadmap forward for ProTrans.
An unacceptable misunderstanding is circulating in the market
Our jaws drop to the floor when we see the market selling Immunovia on the back of a press release that essentially confirmed the technical performance of IMMray PanCan-d, once again corroborating the robustness of the IMMray platform technology.
As expected, the verification study demonstrated outstanding diagnostic accuracy in line with the previous commercial test model study.read more
Vator Securities advises A3P Biomedical on 110 MSEK Private Placement
Vator Securities acts as Financial Advisor in connection with the transaction raising SEK 110 million.
The SEK 110 million in growth capital was raised from institutional and private investors in Sweden to fund the commercialization of Stockholm3, A3P’s superior prostate cancer test.read more
Equity Sales – Corporate Finance till Vator Securities
I rollen inom Equity Sales kommer ditt fokus att ligga på daglig kontakt med Vator Securities kunder gällande olika emissionserbjudanden.
Du erbjuds en utmanade och utvecklande tjänst i ett snabbväxande bolag med högt driv och engagemang där du kommer att utgöra en viktig del av ett sammansvetsat team och få en unik möjlighet att bli en del av ett framgångsrikt team.read more
Diamyd® on track for Phase III with 50% LOA, targeting a multibillion-dollar market as a precision medicine game changer
As of September 15th, 2020, the company that was founded in 1984 delivered convincing top-line data – in line with medical consensus view of implementing precision medicine – consistently supporting positive effect of the first-in-class disease-modifying diabetes vaccine Diamyd® in a genetically defined group.
We initiate coverage with an Outperform rating. With a 50% LOA for the lead candidate Diamyd® and 18% LOA for Remygen® our risk-adjusted DCF valuation results in a value for Diamyd Medical of SEK 100 per share, corresponding to an equity value of approximately SEK 6.6 bn non diluted.read more
110 MSEK | Q3 2020
40,5 MSEK | Q2 2020
59,3 MSEK | Q2 2020
400 MSEK | Q2 2020
146 MSEK | Q2 2020
25 MSEK | Q2 2020
25 MSEK | Q2 2020
21,7 MSEK | Q4 2019
106 MSEK | Q4 2019
106 MSEK | Q2 2019
40 MSEK | Q2 2019
238 MSEK | Q2 2019
70 MSEK | Q2 2019
59 MSEK | Q1 2019
200 MSEK | Q1 2019
200 MSEK | Q4 2018
71 MSEK | Q2 2018